Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with platinum-based chemotherapy then maintenance pembrolizumab within its marketing authorisation for the treatment of advanced or recurrent endometrial cancer.
Status In progress
Technology type Medicine
Decision Awaiting decision
Process STA Standard
ID number 6381

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6381 20 May 2024 - 18 June 2024

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
20 May 2024 In progress. Scoping commencing
24 November 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
24 November 2023 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual